{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:44:54Z","timestamp":1787316294820,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum toxin (BoTX) is the standard treatment for task-specific dystonias (TSDs) such as musician\u2019s dystonia (MD). Our aim was to assess the long-term changes in BoTX treatment in a highly homogeneous and, to our knowledge, largest group of MD patients with respect to the following parameters: (1) absolute and (2) relative BoTX dosage, (3) number of treated muscles, and (4) inter-injection interval. We retrospectively assessed a treatment period of 20 years in 233 patients, who had received a cumulative dose of 68,540 MU of BoTX in 1819 treatment sessions, performed by two neurologists. Nonlinear correlation was used to analyze changes in the parameters over the course of repeated treatments. Post-hoc we applied a median-split to classify two subgroups (high-BoTX, low-BoTX) depending on the total amount of BoTX needed during treatment. Across all patients, we found a decrease of dosage for the first approximately 25 treatments with an increase afterwards. The number of muscles and inter-injection intervals increased with time with a discrete decrease of inter-injection intervals after about 35 treatments. Subgroup differences were observed in the amount of BoTX and inter-injection intervals, with continuously increasing inter-injection intervals and decreasing BoTX dosage in the low-BTX group. Both groups showed a continuously increasing number of injected muscles. In summary, we found nonlinear changes of BoTX dosage and inter-injection intervals and a continuously increasing number of injected muscles with treatment duration in TSD-patients. Furthermore, we, for the first time, identified two subgroups with distinct differences. Increasing inter-injection intervals and decreasing BoTX dosages in the low-BoTX group indicated improvement of symptoms with continued treatment. Continually increasing BoTX dosages with unchanged inter-injection intervals in the high-BoTX group indicated deterioration.<\/jats:p>","DOI":"10.3390\/toxins13060371","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T02:32:43Z","timestamp":1621823563000},"page":"371","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment"],"prefix":"10.3390","volume":"13","author":[{"given":"Andr\u00e9","family":"Lee","sequence":"first","affiliation":[{"name":"Institute of Music Physiology and Musicians\u2019 Medicine, University of Music, Drama and Media Hannover, Neues Haus 1, 30175 Hanover, Germany"},{"name":"Department of Neurology, Klinikum Rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Ismaningerstr. 22, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3095-609X","authenticated-orcid":false,"given":"Jabreel","family":"Al-Sarea","sequence":"additional","affiliation":[{"name":"Hanover Medical School, Carl-Neuberg-Str. 1, 30625 Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckart","family":"Altenm\u00fcller","sequence":"additional","affiliation":[{"name":"Institute of Music Physiology and Musicians\u2019 Medicine, University of Music, Drama and Media Hannover, Neues Haus 1, 30175 Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5334\/tohm.223","article-title":"Focal Task-specific Dystonia-From Early Descriptions to a New, Modern Formulation","volume":"4","author":"Frucht","year":"2014","journal-title":"Tremor. Other Hyperkinet. Mov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1055\/s-0038-1673596","article-title":"Musikerdystonien: Ph\u00e4nomenologie, Ursachen, Differenzialdiagnosen und Behandlungsm\u00f6glichkeiten","volume":"37","author":"Lee","year":"2018","journal-title":"Nervenheilkunde"},{"key":"ref_3","first-page":"97","article-title":"Fokale Dystonie bei Instrumentalmusikern als Berufskrankheit (BK 2115)","volume":"69","author":"Spallek","year":"2019","journal-title":"Zent. Arb. Arb. Ergon."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21091\/mppa.2010.1002","article-title":"Focal dystonia in musicians: Phenomenology, pathophysiology, triggering factors, and treatment","volume":"25","author":"Jabusch","year":"2010","journal-title":"Med. Probl. Perform. Art"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Frucht, S.J. (2018). Phenomenology of Musician\u2019s Dystonia A Window into Task-Specific Dystonia. Treatment of Dystonia, Cambridge University Press. [1st ed.].","DOI":"10.1016\/j.parkreldis.2019.02.023"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/mds.26893","article-title":"Changes in resting-state connectivity in musicians with embouchure dystonia","volume":"32","author":"Haslinger","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.12688\/f1000research.21029.2","article-title":"Advances in the pathophysiology of adult-onset focal dystonias: Recent neurophysiological and neuroimaging evidence","volume":"9","author":"Conte","year":"2020","journal-title":"F1000Research"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1196\/annals.1444.012","article-title":"Task-specific Dystonias","volume":"1142","author":"Perlmutter","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Dressler, D., Altenm\u00fcller, E., and Krauss, J.K. (2018). Treatment of Musician\u2019s Dystonia with Botulinum Toxin. Treatment of Dystonia, Cambridge University Press. [1st ed.].","DOI":"10.1017\/9781316459324"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","article-title":"Long-term follow-up of cervical dystonia patients treated with botulinum toxin A: Long-Term Botulinum Toxin Treatment in CD","volume":"19","author":"Haussermann","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial: Incobotulinumtoxina in Blepharospasm","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins5020249","article-title":"Long-term efficacy and safety of botulinum toxin injections in dystonia","volume":"5","author":"Jankovic","year":"2013","journal-title":"Toxins"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/jnnp-2012-303608","article-title":"Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia","volume":"84","author":"Dressler","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/lary.23265","article-title":"Oromandibular dystonia: Long-term management with botulinum toxin","volume":"123","author":"Sinclair","year":"2013","journal-title":"Laryngoscope"},{"key":"ref_16","first-page":"186","article-title":"Changes in dose and injection pattern in the botulinum toxin long-term therapy of facial dyskinesis","volume":"93","author":"Laskawi","year":"2014","journal-title":"Laryngorhinootologie"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00702-014-1278-z","article-title":"Blepharospasm: Long-term treatment with either Botox\u00ae, Xeomin\u00ae or Dysport\u00ae","volume":"122","author":"Kollewe","year":"2015","journal-title":"J. Neural Transm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00415-019-09349-2","article-title":"Treatment of cervical dystonia with abo- and onabotulinumtoxinA: Long-term safety and efficacy in daily clinical practice","volume":"266","author":"Jochim","year":"2019","journal-title":"J. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00415-019-09581-w","article-title":"Treatment of blepharospasm and Meige\u2019s syndrome with abo- and onabotulinumtoxinA: Long-term safety and efficacy in daily clinical practice","volume":"267","author":"Jochim","year":"2020","journal-title":"J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: A cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J. Med. Econ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2014.925462","article-title":"Satisfaction with botulinum toxin treatment in post-stroke spasticity: Results from two cross-sectional surveys (patients and physicians)","volume":"17","author":"Bensmail","year":"2014","journal-title":"J. Med. Econ."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0733-8619(08)80005-9","article-title":"Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia","volume":"26","author":"Swope","year":"2008","journal-title":"Neurol. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.toxicon.2015.09.037","article-title":"Is it time for flexibility in botulinum inter-injection intervals?","volume":"107","author":"Ojo","year":"2015","journal-title":"Toxicon"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jns.2014.08.004","article-title":"IncobotulinumtoxinA (Xeomin\u00ae) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated","volume":"346","author":"Evidente","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/mds.23504","article-title":"Long-term follow-up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more","volume":"26","author":"Lungu","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0002-9394(03)00075-8","article-title":"Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm","volume":"136","author":"Snir","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","article-title":"Long-term botulinum toxin efficacy, safety, and immunogenicity","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12640-009-9023-3","article-title":"Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs","volume":"15","author":"Bentivoglio","year":"2009","journal-title":"Neurotox. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s00115-008-2486-2","article-title":"Langzeittherapie fokaler Dystonien und des Hemispasmus facialis mit Botulinum-Toxin, A","volume":"79","author":"Vogt","year":"2008","journal-title":"Nervenarzt"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mds.870060110","article-title":"Writer\u2019s cramp: Treatment with botulinum toxin injections","volume":"6","author":"Rivest","year":"1991","journal-title":"Mov. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mds.870100411","article-title":"Double-Blind trial of botulinum toxin for treatment of focal hand dystonia","volume":"10","author":"Cole","year":"1995","journal-title":"Mov. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dressler, D., Altavista, M.C., Altenmueller, E., Bhidayasiri, R., Bohlega, S., Chana, P., Chung, T.M., Colosimo, C., Fheodoroff, K., and Garcia-Ruiz, P.J. (2021). Consensus guidelines for botulinum toxin therapy: General algorithms and dosing tables for dystonia and spasticity. J. Neural Transm., Available online: http:\/\/link.springer.com\/10.1007\/s00702-021-02312-4.","DOI":"10.1007\/s00702-021-02312-4"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00702-014-1165-7","article-title":"IncobotulinumtoxinA (Xeomin(\u00ae)) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport(\u00ae))","volume":"121","author":"Dressler","year":"2014","journal-title":"J. Neural Transm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ene.12330","article-title":"The Dystonia Discomfort Scale (DDS): A novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia","volume":"21","author":"Dressler","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1468-1331.2006.01446.x","article-title":"Botulinum toxin therapy of writer\u2019s cramp","volume":"13","author":"Das","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00702-013-1076-z","article-title":"Botulinum toxin therapy of cervical dystonia: Comparing onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae)","volume":"121","author":"Dressler","year":"2014","journal-title":"J. Neural Transm."},{"key":"ref_37","unstructured":"Stacey, M.A. (2006). Handbook of Dystonia, Informa Healthcare."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Scaglione, F. (2016). Conversion Ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in Clinical Practice. Toxins, 8.","DOI":"10.3390\/toxins8030065"},{"key":"ref_39","unstructured":"Ranjan, C., and Najari, V. (2020, December 01). nlcor: Nonlinear Correlation. Available online: http:\/\/rgdoi.net\/10.13140\/RG.2.2.10123.72488."},{"key":"ref_40","unstructured":"Ranjan, C. (2020, December 01). Package \u201cnlcor\u201d: Compute Nonlinear Correlations. Available online: http:\/\/rgdoi.net\/10.13140\/RG.2.2.33716.68480."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/6\/371\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:05:58Z","timestamp":1760162758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/6\/371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["toxins13060371"],"URL":"https:\/\/doi.org\/10.3390\/toxins13060371","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]}}}